Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The dilemma of prostate-specific antigen testing.

Leach R, Thompson IM.

Arch Intern Med. 2012 Jun 11;172(11):835-6. No abstract available.

2.

Diagnostic challenges of clonal heterogeneity in prostate cancer.

Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB.

J Clin Oncol. 2015 Mar 1;33(7):e38-40. doi: 10.1200/JCO.2013.50.3540. No abstract available.

PMID:
24638011
3.

New tests for prostate cancer.

O'Hanlon LH.

J Natl Cancer Inst. 2013 Nov 20;105(22):1672-4. doi: 10.1093/jnci/djt344. No abstract available.

PMID:
24198330
4.

Prognosis: Proportionate response.

DeWeerdt S.

Nature. 2015 Dec 17;528(7582):S124-5. doi: 10.1038/528S124a. No abstract available.

PMID:
26672783
5.

Prostate cancer: measuring PSA.

Pezaro C, Woo HH, Davis ID.

Intern Med J. 2014 May;44(5):433-40. doi: 10.1111/imj.12407. Review.

PMID:
24816306
6.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

Urol Oncol. 2013 Jul;31(5):566-71. doi: 10.1016/j.urolonc.2011.04.001.

7.

Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?

Schriefer P, Steurer S, Huland H, Graefen M.

J Clin Oncol. 2012 Nov 10;30(32):e341-4. doi: 10.1200/JCO.2012.43.1767. No abstract available.

PMID:
23032622
8.

Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas T, Pandis N.

Anticancer Res. 2013 Jan;33(1):191-7.

PMID:
23267145
9.

Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

Perdonà S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, Franco R, Azzarito G, Scala S, Arra C, De Sio M, Autorino R.

Eur Urol. 2011 Jan;59(1):81-7. doi: 10.1016/j.eururo.2010.09.036.

PMID:
20947244
10.

Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

Wilt TJ, Scardino PT, Carlsson SV, Basch E.

J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. No abstract available.

11.

The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.

Stattin K, Sandin F, Bratt O, Lambe M.

J Urol. 2015 Dec;194(6):1594-600. doi: 10.1016/j.juro.2015.07.082.

PMID:
26192253
12.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013.

PMID:
21601352
13.

Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries.

Okihara K, Ochiai A, Kamoi K, Fujizuka Y, Miki T, Ito K.

Int J Urol. 2015 Apr;22(4):334-41. doi: 10.1111/iju.12701. Review.

14.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011.

15.

Prostate-specific antigen dynamics and prostate cancer diagnosis.

Bartoletti R.

Eur Urol. 2009 Nov;56(5):761-2; discussion 763. doi: 10.1016/j.eururo.2009.07.048. No abstract available.

PMID:
19665286
16.

Prostate cancer antigen 3 and genetic risk score as markers for the detection of prostate cancer in the Chinese population.

Wei HM, Chen HT, Wang P, Wu YS, Na R, Liu F, Sun JS, Jiang DK, Lu DR, Xu J.

Asian J Androl. 2015 Jan-Feb;17(1):168-70. doi: 10.4103/1008-682X.143245. No abstract available.

17.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Review.

PMID:
21871709
18.

National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath K, Wessells H.

Ann Intern Med. 2012 Apr 17;156(8):591-5. doi: 10.7326/0003-4819-156-8-201204170-00401. No abstract available.

19.

[Prostate cancer].

Hefermehl L, Elke B, Sulser T.

Praxis (Bern 1994). 2010 Feb 3;99(3):149-56, 158; quiz 157. doi: 10.1024/1661-8157/a000044. German. No abstract available.

PMID:
20127633
20.

New tests for prostate cancer may be nearing the clinic.

Tuma RS.

J Natl Cancer Inst. 2010 Jun 2;102(11):752-4. doi: 10.1093/jnci/djq210. No abstract available.

PMID:
20498428

Supplemental Content

Support Center